Statin Therapy

CHICAGO — In Japanese adults with chronic CAD already treated with statin therapy, highly purified eicosapentaenoic acid showed borderline statistical significance in reducing risk for adverse CV events, researchers reported.

Last week, Healio provided live coverage of the American Heart Association Scientific Sessions.

CHICAGO — Daily rosuvastatin lowered LDL, total cholesterol and serum triglycerides significantly more than placebo and six common over-the-counter dietary supplements, with no supplement lowering LDL more than placebo, researchers reported.

Healio and Cardiology Today have curated a list of the most-read news in cardiology of October 2022.

In August, the U.S. Preventive Services Task Force published a statement recommending statins for the primary prevention of CVD in patients aged 40 to 75 years with at least one CVD risk factor and 10% or greater 10-year risk for CVD.

Fewer than half of veterans, most of whom were not on lipid-lowering therapy before an event, received intensified lipid-lowering therapies after an MI or elective revascularization, researchers reported.

The U.S. Preventive Services Task Force in August published a statement regarding the initiation of statin therapy for the primary prevention of atherosclerotic CVD.

There are drug-drug interactions between the COVID-19 treatment ritonavir/nirmatrelvir and various classes of commonly used CV medications, according to a review paper.

In August, the U.S. Preventive Services Task Force released a new recommendation statement on the use of statin therapy for primary prevention of CVD. Like its 2016 guidelines, the USPSTF recommended statins as primary prevention for adults aged 40 to 75 years with at least one CVD risk factor and a 10% or greater 10-year risk for CVD.

The European Society of Cardiology Congress was held Aug. 26 to 29 in Barcelona, Spain, and online, having an in-person component for the first time since 2019.